MedCity News November 29, 2021
Frank Vinluan

Quell Therapeutics’ $156 million Series B round comes as it prepares to advance to a clinical trial testing its lead regulatory T cell therapy candidate as way to prevent organ rejection in liver transplant patients. The progress comes as the field of Treg cell therapy research becomes increasingly competitive.

Organ transplants require drugs that reduce the chances of the body rejecting a donor organ, but these immuno-suppressive therapies also raise the risk of infection. That risk is ongoing as anti-rejection therapies must be taken for life. Quell Therapeutics aims to offer an alternative: an immune cell engineered into a cell therapy that prevents organ rejection. The biotech is approaching its first clinical test and on Monday it unveiled $156 million...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Covid’s scientific silver lining: A chance to watch the human immune system respond in real time
How GLP-1’s moved from research labs to national TV
Understanding the politics of drug pricing in the United States
Opinion: Oprah kicked off a national conversation on obesity and GLP-1 drugs. Let’s have it
Brazil’s plan for low-cost CAR-Ts

Share This Article